Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction
AssigneeVivus, Inc.
InventorsPaul C. Doherty, Jr., Virgil A. Place, William L. Smith
Life of this patent
Estimating the term…
Abstract
A method is provided for treating erectile dysfunction, e.g., vasculogenic erectile dysfunction such as vasculogenic impotence. The method involves the administration of a Type IV phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or derivative thereof, wherein administration is local, i.e., transurethral, intracavernosal, topical or transdermal. A preferred mode of administration is transurethral. Pharmaceutical formulations and kits are provided as well.
Claims106
A method for treating erectile dysfunction in a male individual, comprising locally administering to the individual a therapeutically effective amount of a pharmaceutical formulation comprised of a Type IV phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or prodrug thereof.
A pharmaceutical formulation for treating erectile dysfunction comprising a therapeutically effective amount of a Type IV phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or prodrug thereof, and a pharmaceutically acceptable carrier suitable for local drug administration.
A kit for treating erectile dysfunction, comprising:
- a pharmaceutical formulation containing a Type IV phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or prodrug thereof;
- a means for locally administering the formulation;
- a container for housing the formulation and drug delivery means;
- and instructions for using the drug delivery means to administer the formulation within the context of a dosing regimen effective to treat erectile dysfunction.
Dependencies are inferred from the claim text.